-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect
-- Narrow...
Delivering SDR-powered capacity scaling, single-person deployment, and off-grid readiness, the new digital integrated base station cuts CAPEX and OPEX and deployment friction across public safety, ene...
New facility marks a major milestone in SES' transformation and redefinition of traditional space industry models, designed to accelerate innovation, optimization of supply chain, and expansion of SES...
